BAVA:VIE
Bavarian Nordic A/S
31,50 €
arrow_downward
-0,63%(-0,20) 1D
14 ოქტ, 17:36:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAVA...
Open
31,66 €
High
31,74 €
Low
31,38 €
Mkt. cap
2,77 მლრდ.
Avg. vol.
17,00
Volume
0,00
52-wk high
32,47 €
52-wk low
22,96 €
No. of employees
2 ათ.
Open
31,66 €
High
31,74 €
Low
31,38 €
Mkt. cap
2,77 მლრდ.
Avg. vol.
17,00
Volume
0,00
52-wk high
32,47 €
52-wk low
22,96 €
No. of employees
2 ათ.
News stories
From web sources and news partners
Stock Titan
·
1 საათის წინ
West Coast Community Bank ranked No. 12 among the top 25 publicly traded banks.
Yahoo Finance
·
38 წუთის წინ
Invesco QQQ Doesn't Own a Single Bank, and That's Not the Only Thing the Nasdaq-100 Leaves Out
Simply Wall Street
·
33 წუთის წინ
Lumentum Is Up 472% Even As It Swung To A Loss
Bloomberg.com
·
3 საათის წინ
S&P 500 Ends Longest Streak of Calm Since 2020 as AI Trade Sinks
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S